| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
HT-61 targets bacterial cell wall and division processes in gram-positive bacteria. It effectively reduces biofilm viability and is associated with increased expression of cell wall stress and division proteins. Its mechanism of action is distinct from traditional antibiotics, making it effective against resistant strains such as MRSA. It also enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.
|
|---|---|
| ln Vitro |
HT-61 exhibits bactericidal activity against gram-positive bacteria, including MSSA and MRSA. It effectively reduces biofilm viability and is associated with increased expression of cell wall stress and division proteins. It enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro. Its activity has been confirmed in various antimicrobial susceptibility tests.
|
| ln Vivo |
HT-61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vivo. Its ability to treat staphylococcal infections has been demonstrated in preclinical studies. The compound shows potential for the treatment of biofilm-associated infections. However, detailed in vivo efficacy data against staphylococcal infections is limited in the available literature.
|
| Enzyme Assay |
The primary in vitro assay for HT-61 is the minimum inhibitory concentration (MIC) determination using broth microdilution or agar dilution methods. The compound is tested against various bacterial strains, including MSSA and MRSA, to determine its antibacterial activity. Biofilm assays are performed to assess its ability to reduce biofilm viability. Combination studies with other antibiotics, such as tobramycin, are also conducted.
|
| Cell Assay |
In vitro cellular experiments for HT-61 involve treating bacterial cultures with the compound and measuring its effects on bacterial growth and viability. Time-kill kinetics are assessed by measuring colony-forming units over time. The compound's effects on biofilm formation and viability are assessed using crystal violet staining or confocal microscopy. Its effects on cell wall stress and division protein expression can be assessed by Western blot or qPCR.
|
| Animal Protocol |
In vivo animal experiments for HT-61 have been conducted to assess its efficacy in enhancing the effect of tobramycin against Pseudomonas aeruginosa. It could also be evaluated in animal models of staphylococcal infection to assess its antibacterial efficacy. Its pharmacokinetic properties and safety profile would be characterized in these studies.
|
| ADME/Pharmacokinetics |
HT-61 has a molecular weight of 380.5 g/mol and a molecular formula of C26H24N2O. It is a pyrroloquinolone antibiotic. The compound is supplied as a powder and is soluble in DMSO. It is stored at -20°C for long-term stability. Its purity is typically ≥98%.
|
| Toxicity/Toxicokinetics |
HT-61 is a research compound that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. As with all research chemicals, standard safety precautions should be followed when handling. Its safety would need to be established for therapeutic applications.
|
| References |
Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02073-19.
|
| Additional Infomation |
HT-61 (HY-50A) is a novel and potent pyrroloquinolone-based antibiotic with activity against gram-positive bacteria, including MSSA and MRSA. It effectively reduces biofilm viability and enhances the effect of tobramycin against Pseudomonas aeruginosa. The compound is being investigated for the treatment of staphylococcal infections and is available from various chemical suppliers for research purposes.
|
| Molecular Formula |
C26H24N2O
|
|---|---|
| Molecular Weight |
380.481566429138
|
| Exact Mass |
380.188
|
| Elemental Analysis |
C, 82.07; H, 6.36; N, 7.36; O, 4.20
|
| CAS # |
936622-80-9
|
| Related CAS # |
936622-80-9;
|
| PubChem CID |
16727326
|
| Appearance |
Solid powder
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C(C)=C2CCN(C2=C2C=1C=CC(=C2)OC1C=CC=CC=1)CCC1C=CC=CC=1
|
| InChi Key |
XCZMUTGHJBFKPM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H24N2O/c1-19-23-15-17-28(16-14-20-8-4-2-5-9-20)26(23)24-18-22(12-13-25(24)27-19)29-21-10-6-3-7-11-21/h2-13,18H,14-17H2,1H3
|
| Chemical Name |
4-methyl-1-phenethyl-8-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline
|
| Synonyms |
HT 61; HT61; HT-61
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
